Cargando…

The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma

BACKGROUND: Recent studies have suggested a significant relationship between inflammatory indexes such as the neutrophil-to-lymphocyte ratio (NLR) and survival outcomes in various cancers. The aim of the present study was to evaluate the prognostic value of 6 pretreatment inflammatory markers in pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Manni, Wu, Shuang, Tong, An, Cui, Xiwei, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709794/
https://www.ncbi.nlm.nih.gov/pubmed/31686912
http://dx.doi.org/10.2147/CMAR.S219237
_version_ 1783446242112569344
author Wang, Manni
Wu, Shuang
Tong, An
Cui, Xiwei
Ma, Xuelei
author_facet Wang, Manni
Wu, Shuang
Tong, An
Cui, Xiwei
Ma, Xuelei
author_sort Wang, Manni
collection PubMed
description BACKGROUND: Recent studies have suggested a significant relationship between inflammatory indexes such as the neutrophil-to-lymphocyte ratio (NLR) and survival outcomes in various cancers. The aim of the present study was to evaluate the prognostic value of 6 pretreatment inflammatory markers in patients with primary angiosarcoma (AS) which is a rare and highly malignant type of soft tissue sarcoma. METHODS: Fifty-six patients diagnosed with primary AS at West China Hospital between August 2009 and July 2016 were retrospectively enrolled. The value of each biomarker was calculated for its correlation with patients’ overall survival. RESULTS: The low tumor grade, tumor size <5 cm, metastatic status, surgical treatment and low level of monocyte-to-lymphocyte ratio, NLR and lactate dehydrogenase (LDH) were correlated with better survival outcome in univariate analyses. In multivariate analyses, high levels of NLR (HR 2.673, 95% CI 1.253–5.703, p=0.011) and LDH (HR 2.964, 95% CI 1.464–5.998, p=0.003) were selected as independent prognostic factors. CONCLUSION: This study identifies the elevated pretreatment levels of NLR and LDH as prognostic markers in patients with primary AS.
format Online
Article
Text
id pubmed-6709794
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67097942019-11-04 The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma Wang, Manni Wu, Shuang Tong, An Cui, Xiwei Ma, Xuelei Cancer Manag Res Original Research BACKGROUND: Recent studies have suggested a significant relationship between inflammatory indexes such as the neutrophil-to-lymphocyte ratio (NLR) and survival outcomes in various cancers. The aim of the present study was to evaluate the prognostic value of 6 pretreatment inflammatory markers in patients with primary angiosarcoma (AS) which is a rare and highly malignant type of soft tissue sarcoma. METHODS: Fifty-six patients diagnosed with primary AS at West China Hospital between August 2009 and July 2016 were retrospectively enrolled. The value of each biomarker was calculated for its correlation with patients’ overall survival. RESULTS: The low tumor grade, tumor size <5 cm, metastatic status, surgical treatment and low level of monocyte-to-lymphocyte ratio, NLR and lactate dehydrogenase (LDH) were correlated with better survival outcome in univariate analyses. In multivariate analyses, high levels of NLR (HR 2.673, 95% CI 1.253–5.703, p=0.011) and LDH (HR 2.964, 95% CI 1.464–5.998, p=0.003) were selected as independent prognostic factors. CONCLUSION: This study identifies the elevated pretreatment levels of NLR and LDH as prognostic markers in patients with primary AS. Dove 2019-08-22 /pmc/articles/PMC6709794/ /pubmed/31686912 http://dx.doi.org/10.2147/CMAR.S219237 Text en © 2019 Wang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Wang, Manni
Wu, Shuang
Tong, An
Cui, Xiwei
Ma, Xuelei
The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma
title The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma
title_full The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma
title_fullStr The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma
title_full_unstemmed The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma
title_short The prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma
title_sort prognostic value of pretreatment inflammatory biomarkers in primary angiosarcoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709794/
https://www.ncbi.nlm.nih.gov/pubmed/31686912
http://dx.doi.org/10.2147/CMAR.S219237
work_keys_str_mv AT wangmanni theprognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma
AT wushuang theprognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma
AT tongan theprognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma
AT cuixiwei theprognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma
AT maxuelei theprognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma
AT wangmanni prognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma
AT wushuang prognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma
AT tongan prognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma
AT cuixiwei prognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma
AT maxuelei prognosticvalueofpretreatmentinflammatorybiomarkersinprimaryangiosarcoma